CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 65,177 enrolled
Drug / intervention
Scorecard +3 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06066541
NCT06066541N/ACompleted

Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence

Brigham and Women's Hospital·interventional·Posted Oct 4, 2023·Updated Jan 14, 2025

In Brief

A clinical study evaluating Scorecard, Social norms, and 2 other interventions for Medication Adherence and Hypertension. Completed, enrolled 65,177 participants across 1 site.

Detailed Summary

Medicare Advantage beneficiaries ages 65-79 and insured by Humana with at least two unique fills of hypertension medication within the 2023 calendar year and adherence level between 60 and 85% will be identified using Humana Medicare Advantage claims data. Individuals meeting these inclusion criteria will be included and, with an institutional review board approved waiver of informed consent, will be randomized to one of 6 mailed messages or control (no message). The messages will be sent by Humana and use different behavioral techniques (social norms, messenger effects, and/or processing fluency) providing their medication refill score. Humana will send a second message within 60 days of the first message noting any changes in the refill score. The primary outcome will be the average end-of-year adherence in each arm. A secondary outcome will be the proportion of study participants with end-of-year adherence greater than or equal to 80%. The study team's hypothesis is that messages using dynamic social norms, messenger effects, and processing fluency in combination will more effectively increase average end-of-year adherence level compared to usual care. Humana will conduct all study participant outreach and data analyses, which will be performed using routinely collected insurance claims data. Regulatory oversight is conducted using Humana's centralized institutional review board (IRB) of record. The work completed by Humana study staff is funded by Humana, Inc. Dr. Choudhry and his colleagues (including subaward recipients ideas42 and Tuck School of Business at Dartmouth) will provide technical and subject matter expertise related to study research design and implementation, protocol design, statistical analysis, publication (abstract, poster, manuscript) preparation and/or review, and assistance throughout the peer review process including revisions and additional analyses if necessary for this project. The work completed by study staff at Brigham and Women's Hospital, ideas42, and Tuck School of Business at Dartmouth is funded by NIA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
202420252026
First PostedOct 4, 2023
Enrollment StartAug 18, 2023
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.7 years ago

Interventions

Scorecardbehavioral

Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a "refill score."

Social normsbehavioral

Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).

Messenger effectsbehavioral

Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.

Processing fluencybehavioral

Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of "closing the ring."